基于二代测序技术探究食管鳞癌分子生物学特征及临床意义

doi:10.6040/j.issn.1671-7554.0.2019.650

摘要/Abstract

摘要： 目的利用二代测序技术(NGS)对基因突变频率进行分析,探究食管鳞癌(ESCC)基因突变特征,寻找潜在的靶向治疗和免疫治疗靶点。方法随机收集49例山东省立医院确诊的ESCC患者的石蜡肿瘤组织样本,进行DNA提取,采用Illumina HiSeq4000测序平台对416个肿瘤相关基因进行捕获测序,测序结果进行生物信息学分析。结果发现TP53基因突变频率最高,并发现了多个ESCC潜在治疗靶点。EGFR 19del突变率和扩增率均为4.08%,未见EGFR L858R突变及KRAS突变;HER2和MET基因扩增发生率均为2.04%;BRCA1/2基因失活突变率约为8.06%;另外,MSI阳性率约为4.76%。提示携带相关靶点突变的患者可能是靶向治疗或免疫治疗的潜在获益人群。结论通过高通量检测技术发现ESCC多个潜在治疗靶点,对患者临床治疗方案的制定有重要意义。

关键词: 食管鳞癌, 二代测序, 基因变异, 靶向治疗

Abstract: Objective To explore the potential molecular targets and gene mutation characteristics in esophageal squamous cell carcinoma(ESCC)by using next-generation sequencing. Methods DNA was extracted from tissue samples collected from 49 ESCC patients. The 416 cancer-relevant genes were sequenced with Illumina HiSeq4000 platform. The sequencing data were then subjected to bioinformatics analysis. Results TP53 was identified as the most frequently mutated gene, and multiple potential therapeutic targets were revealed. The mutation rate and amplification rate of EGFR 19del mutations were both 4.08%, while no EGFR L858R mutation or KRAS mutation was detected. The amplification rate of HER2 and MET were both 2.04%. The inactivating mutation rate of BRCA1/2 was 8.06%. The positive rate of MSI was 4.76%, indicating that ESCC patients with related target gene variations would potentially benefit from targeted therapies or immunotherapies. Conclusion Multiple potential therapeutic targets in ESCC are identified using next-generation sequencing, which can significantly guide personalized ESCC treatment.

Key words: Esophageal squamous cell carcinoma, Next-generation sequencing, Gene mutation, Targeted therapy

中图分类号:

R574

冯阿磊,董青,逄娇慧,殷嘉妮,李强,韩俊庆,杨哲. 基于二代测序技术探究食管鳞癌分子生物学特征及临床意义[J]. 山东大学学报 (医学版), 2019, 57(7): 80-85.

FENG Alei, DONG Qing, PANG Jiaohui, YIN Jiani, LI Qiang, HAN Junqing, YANG Zhe. Exploring molecular characteristics of esophageal squamous cell carcinoma based on next-generation sequencing[J]. Journal of Shandong University (Health Sciences), 2019, 57(7): 80-85.

参考文献

[1] Kang X, Chen K, Li Y, et al. Personalized targeted therapy for esophageal squamous cell carcinoma[J]. World J Gastroenterol, 2015, 21(25): 7648-7658.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Chen XX, Zhong Q, Liu Y, et al. Genomic comparison of esophageal squamous cell carcinoma and its precursor lesions by multi-region whole-exome sequencing[J]. Nat Commun, 2017, 8(1): 524.
[4] Chen J, Kwong DL, Cao T, et al. Esophageal squamous cell carcinoma(ESCC): advance in genomics and molecular genetics[J]. Dis Esophagus, 2015, 28(1): 84-89.
[5] Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data[J]. Cancer Discov, 2012, 2(5): 401-404.
[6] Gao J, Aksoy BA, Dogrusoz U, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal[J]. Sci Signal, 2013, 6(269): pl1.
[7] Zhou C. Lung cancer molecular epidemiology in China: recent trends[J]. Transl Lung Cancer Res, 2014, 3(5): 270-279.
[8] Guo K, Wang WP, Jiang T, et al. Assessment of epidermal growth factor receptor mutation/copy number and K-ras mutation in esophageal cancer[J]. J Thorac Dis, 2016, 8(7): 1753-1763.
[9] Huang J, Fan Q, Lu P, et al. Icotinib in patients with pretreated advanced esophageal squamous cell carcinoma with EGFR overexpression or EGFR gene amplification: a single-arm, multicenter phase 2 study[J]. J Thorac Oncol, 2016, 11(6): 910-917.
[10] Petty RD, Dahle-Smith A, Miedzybrodzka Z, et al. Epidermal growth factor receptor copy number gain(EGFR CNG)and response to gefitinib in esophageal cancer(EC): Results of a biomarker analysis of a phase Ill trial of gefitinib versus placebo(TRANS-COG)[J]. J Clin Oncol, 2014, 32(15):4016.
[11] Perez EA, Romond EH, Suman VJ. et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J]. J Clin Oncol, 2014, 32(33):3744-3752.
[12] Kawakami H, Okamoto I, Okamoto W, et al. Targeting MET amplification as a new oncogenic driver[J]. Cancers(Basel), 2014, 6(3): 1540-1552.
[13] Ozawa Y, Nakamura Y, Fujishima F, et al. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target[J]. BMC cancer, 2015, 15(1): 451.
[14] Zhu Y, Wu J, Zhang C, et al. BRCA mutations and survival in breast cancer: an updated systematic review and meta-analysis[J]. Oncotarget, 2016, 7(43): 70113-70127.
[15] Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation(SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2017, 18(9): 1274-1284.
[16] Coleman RL, Oza AM, Lorusso D, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy(ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10106): 1949-1961.
[17] Mirza MR, Monk BJ, Herrstedt J, et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer[J]. N Engl J Med, 2016, 375(22): 2154-2164.
[18] Robson M, Im S A, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation[J]. N Engl J Med, 2017, 377(6): 523-533.
[19] Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation[J]. N Engl J Med, 2018, 379(8): 753-763.
[20] Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer[J]. J Clin Oncol, 2018, 36(8): 773-779.
[21] Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade[J]. Science, 2017, 357(6349): 409-413.
[22] Kudo T, Hamamoto Y, Kato K, et al. Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2017, 18(5): 631-639.
[23] Shah MA, Kojima T, Hochhauser D, et al. Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study[J]. JAMA oncol, 2018.

相关文章 15

[1]	齐硕,刘可宇,徐展望,谭国庆,张强. 改良活检优化宏基因组二代测序腰椎间盘感染早期诊断策略[J]. 山东大学学报 (医学版), 2026, 64(2): 96-103.
[2]	王皓正,张文雄. Q热伴胸腹主动脉瘤支架植入术后感染1例并文献复习[J]. 山东大学学报 (医学版), 2026, 64(1): 126-130.
[3]	葛雪,赵红艳. 疱疹病毒感染对重症肺炎患者临床预后及呼吸道微生态的影响[J]. 山东大学学报 (医学版), 2025, 63(6): 27-37.
[4]	胡家倩,王梦琴,张子夏,王曦,黄爱,杨威,李东晓,卫海燕,罗淑颖,陈永兴. 恩格列净治疗SLC37A4基因变异致糖原累积病Ⅰb型3例患儿并文献复习[J]. 山东大学学报 (医学版), 2025, 63(2): 58-66.
[5]	冯绪梅,宋相庆,季冠虹,赵小刚,肖兆华. 血浆外泌体miR-548k在食管鳞癌中的表达及诊断价值[J]. 山东大学学报 (医学版), 2024, 62(5): 79-88.
[6]	杨闯,张荣雨,宋彬,王程君,赵文,玄甜甜,李际盛. 阿美替尼一线治疗EGFR突变肺腺癌伴大疱性类天疱疮1例并文献复习[J]. 山东大学学报 (医学版), 2024, 62(12): 32-37.
[7]	金晨曦,王钰峰,张倩,李敬,李鸿昌,颜军昊. 男性染色体复杂平衡易位携带者助孕2例并文献复习[J]. 山东大学学报 (医学版), 2023, 61(4): 64-70.
[8]	华月帆,何珂瑶,张家豪,钱梦凡,刘怡文,孔金玉,杨海军,周福有. 具核梭杆菌诱导缺氧诱导因子及血管生成因子高表达对食管鳞癌患者生存预后的影响[J]. 山东大学学报 (医学版), 2023, 61(11): 59-67.
[9]	董媛媛,蒋卫东,刘震,王蘋,李蕃,魏艳,王尚,孟玉洁,徐营营,孙琳. 二代测序辅助诊断水痘-带状疱疹病毒性脑膜炎1例[J]. 山东大学学报 (医学版), 2023, 61(1): 121-124.
[10]	王福立,孙银萍,秦杰,荣建胜. DC-CIK细胞联合EGFR-TKI治疗35例老年晚期EGFR突变肺癌的效果[J]. 山东大学学报 (医学版), 2022, 60(7): 110-117.
[11]	安袁笑雪,杜以明,田甜,张一,薛玉文. 肺炎奴卡菌合并天美奴卡菌肺部感染1例报道并文献复习[J]. 山东大学学报 (医学版), 2022, 60(3): 59-63.
[12]	王婧,刘小转,许芳芳. 肝豆状核变性的ATP7B基因变异分析及产前诊断[J]. 山东大学学报 (医学版), 2022, 60(2): 32-36.
[13]	哈春芳,李茹月. 卵巢癌耐药机制与靶向治疗策略的研究进展[J]. 山东大学学报 (医学版), 2021, 59(9): 117-123.
[14]	陈安静,张训. 靶向小类泛素化修饰的胶质瘤治疗新策略[J]. 山东大学学报 (医学版), 2020, 1(8): 88-94.
[15]	焉传祝,王伟,纪坤乾,赵玉英. 线粒体与脑疾病[J]. 山东大学学报 (医学版), 2020, 1(8): 34-41.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed